01:15 PM EST, 01/08/2025 (MT Newswires) -- Catalyst Pharmaceuticals ( CPRX ) and its licensor SERB have reached a settlement agreement with Teva Pharmaceuticals USA and Teva Pharmaceuticals (TEVA) to resolve the Firdapse patent litigation, Catalyst said Wednesday.

Under the terms of the settlement, Teva will not market its generic version of Firdapse in the US any earlier than Feb. 25, 2035, Catalyst said.

Teva didn't immediately respond to a request for comment from MT Newswires.

Price: 22.65, Change: +3.12, Percent Change: +15.98